{
    "nctId": "NCT00562718",
    "briefTitle": "Capecitabine and Radiation Therapy in Treating Patients With Nonmetastatic Breast Cancer After Surgery",
    "officialTitle": "A Pilot Safety And Feasibility Study Of Concurrent Capecitabine (Xeloda) And External Beam Irradiation In The Adjuvant Treatment Of High Risk Early Stage Breast Cancer.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "Overall Safety",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed invasive adenocarcinoma of the breast, meeting 1 of the following high-risk criteria:\n\n  * T3 or T4 primary tumor\n  * 4 or more involved axillary lymph nodes (N2 nodal stage)\n* Completed surgical excision\n\n  * No immediate reconstruction with autologous flap reconstruction\n\n    * Patients having tissue expanders or implants placed prior to radiation may be enrolled at the physician's discretion\n* No residual breast cancer\n\n  * Microscopically positive margins are allowed if a re-excision is not felt to be clinically justified\n* Candidate for radiotherapy\n\n  * Must not require bilateral radiotherapy\n* No metastatic (stage IV) breast cancer by AJCC staging criteria\n* Hormone receptor status not specified\n* No CNS disorders\n\nPATIENT CHARACTERISTICS:\n\n* Life expectancy \u2265 6 months\n* Karnofsky performance status 70-100%\n* Menopausal status not specified\n* Ambulatory\n* Hemoglobin \\> 9 g/dL\n* Platelet count \\> 100,000/mm\u00b3\n* ANC \\> 1,500/mm\u00b3\n* Serum AST, ALT, and alkaline phosphatase \u2264 2 times upper limit of normal (ULN)\n* Total bilirubin normal\n* Creatinine clearance \\> 50 mL/min\n* Negative pregnancy test\n* Not pregnant or nursing\n* Fertile patients must use effective contraception during study and for 30 days after the last study drug administration\n* No serious, uncontrolled, concurrent infection(s)\n* No diabetes with current or history of delayed wound healing or skin ulcers\n* No autoimmune connective tissue disorder\n* No prior unanticipated severe reaction to fluoropyrimidine therapy, known sensitivity to 5-fluorouracil, or known dihydropyrimidine dehydrogenase (DPD) deficiency\n* No other carcinomas within the last five years except cured non-melanoma skin cancer and in-situ cervical cancer\n* No clinically significant cardiac disease (e.g., congestive heart failure, symptomatic coronary artery disease, or cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months\n* No other serious uncontrolled medical conditions that the investigator feels might compromise study participation, including any of the following:\n\n  * Uncontrolled seizures\n  * Psychiatric disability judged by the investigator to be clinically significant\n* Physically intact upper gastrointestinal tract\n* No malabsorption syndrome\n* No uncompensated coagulopathy\n* No patients whose breast size or body contour puts them at increased risk for skin desquamation from standard radiotherapy\n* Able to read and speak English\n\nPRIOR CONCURRENT THERAPY:\n\n* Fully recovered from surgery and chemotherapy with completely healed surgical wounds\n* At least 4 weeks since completion of prior chemotherapy regimen, excluding trastuzumab (Herceptin\u00ae)\n\n  * Concurrent trastuzumab allowed at the physician's discretion\n* More than 4 weeks since prior participation in any investigational drug study\n* At least 4 weeks since prior and no concurrent sorivudine or brivudine\n* More than 2 weeks since prior major surgery\n* No prior capecitabine\n* No prior radiotherapy to the chest or ipsilateral lymphatics\n* No concurrent hormonal therapy during course of chemotherapy or radiation therapy\n* No concurrent allopurinol or cimetidine\n* Concurrent coumadin is allowed",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}